Human parainfluenza type 4 virus (hPIV4) infection provoking many questions regarding the role of this virus as the causative agent of respiratory tract infections in the post-transplant setting.
Hohenthal
U
U
Nikoskelainen
J
J
Vainionpää
R
R
Peltonen
R
R
Routamaa
M
M
Itälä
M
M
Kotilainen
P
P
D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D003428:Cross Infection / Q000635:transmission; D003937:Diagnosis, Differential; D006801:Humans; D016867:Immunocompromised Host; D010224:Parainfluenza Virus 3, Human / Q000472:pathogenicity*; D029482:Parainfluenza Virus 4, Human / Q000302:isolation & purification / Q000472:pathogenicity*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000821:virology*; D010253:Respirovirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000635:transmission / Q000821:virology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012254:Ribavirin / Q000627:therapeutic use; D019351:Rubulavirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000635:transmission / Q000821:virology*; D014774:Virulence
D000998:Antiviral Agents; D012254:Ribavirin